TO INNOVATIONS

THURSDAY 27 OCTOBER 2016 SYMPOSIA
SYMPOSIUM 14 3 15:15-16:45 3 SESSION ROOM 3A
ENOUGH IS ENOUGH: TIME TO END PREVENTABLE MORTALITY AMONG PEOPLE LIVING WITH HIV
Section: HIV
Despite being preventable and curable, TB is the leading cause of hospitalisation and mortality among people living with HIV (PLHIV), accounting
for some 30 percent of HIV-related deaths in 2014. A recent systematic review of post-mortem studies in resource-limited settings reported TB
accounting for approximately 40 percent of HIV-related deaths, nearly half of which were undetected prior to death. This highlights the urgent need
to increase efforts to enhance access to early detection, timely treatment and prevention. This symposium aims to share the latest evidence and
experience on strategies to expedite diagnosis and reduce TB incidence and mortality among PLHIV.
Co-chairs: Haileyesus Getahun (Switzerland), Riitta Dlodlo (Zimbabwe)
15.15 HIV-associated TB mortality: an irreversible truth? – Nathan Ford (Switzerland)
15.30 Perfecting the TB/HIV screening, diagnostic and treatment algorithm to ensure survival from TB in people living with HIV –
Salome Charalambous (South Africa)
15.45 The role of presumptive TB treatment for improving survival in severely ill patients with HIV – Winceslaus Katagira (Uganda)
16.00 Strategies to end HIV-associated TB mortality are only as good as their implementation: lessons from Zimbabwe – Charles Sandy (Zimbabwe)
16.15 WHO guidance: examining the latest policies and their potential impact on ending mortality from HIV-associated TB –
Annabel Baddeley (Switzerland)
16:30 Discussion
SYMPOSIUM 15 3 15:15-16:45 3 SESSION ROOM 12
NEW APPROACHES AND INNOVATIONS IN TB VACCINE RESEARCH AND DEVELOPMENT
Sub-section: Tuberculosis/Bacteriology & Immunology
A new, effective vaccine against M. tuberculosis will be an important tool to reducing the global burden of this epidemic and addressing the growing
concern of antimicrobial resistance. New vaccines would achieve this by preventing infection and/or disease, thereby reducing the need for antibiotics
and reducing disease transmission. Thus, advancing and accelerating TB vaccine R&D should be a global priority. This session will explore progress
and innovations in the field, with a specific focus on diversifying the TB vaccine portfolio, therapeutic vaccination, mucosal vaccination and local
immunity, and continuing efforts to identify correlates of immunity and protection.
Co-chairs: Willem Hanekom (United States of America), Frank Verreck (Netherlands)
15.15 Diversifying the TB vaccine portfolio – Danilo Casimiro (United States of America)
15.35 The role of a therapeutic vaccine in the fight against tuberculosis – Geneviève Inchauspé (France)
15.55 Pulmonary mucosal vaccination and local immunity – Helen McShane (United Kingdom)
16.15 Searching for correlates of immunity and protection – Thomas Scriba (South Africa)
16:30 Discussion
THURSDAY 27 OCT
SYMPOSIUM 16 3 15:15-16:45 3 SESSION ROOM 11B
QUINOLONES: FROM BENCH TO BEDSIDE
Section: Tuberculosis
Fluoroquinolone resistance is mainly responsible for the worsening prognosis of XDR-TB compared to MDR-TB. In vivo and human data support
the use of fluoroquinolones despite in vitro resistance.
This session will present
1) The updated epidemiological data of resistance to fluoroquinolone
2) Molecular mechanisms responsible for fluoroquinolone resistance and their impact on fluoroquinolone susceptibility
3) The diagnostic performances of existing molecular assays for the diagnosis of fluoroquinolone resistance
4) Animal and clinical studies supporting the use of fluoroquinolones against XDR-TB
Co-chairs: Nicolas Veziris (France), Zaza Avaliani (Georgia)
15.15 Epidemiology of fluoroquinolone resistance in TB in 2016 – Timothy Sterling (United States of America)
15.35 Diagnostic performances of existing molecular and phenotypic assays for the diagnosis of fluoroquinolone resistance –
Alexandra Aubry (France)
15.55 Can fluoroquinolones be used for the treatment of XDR-TB? Lessons from animal studies – Nicolas Veziris (France)
16.15 Can fluoroquinolones be used for the treatment of XDR-TB? Lessons from human studies – Armand van Deun (Belgium)
16:25 Discussion
26-29 OCTOBER 2016 - LIVERPOOL - UNITED KINGDOM
69